GenVec Halts Human Testing of Top Drug GenVec Inc. has suspended human testing of its leading drug, a potential cancer therapy, after a patient died during a study. Its stock closed at \$1.20, down \$1.06. But analysts said the link between the death and the drug has yet to be proved. &lt;BR&gt;&lt;FONT face="verdana,MS Sans Serif,arial,helvetica" size="-2"\ color="#666666"&gt;&lt;B&gt;-The Washington Post&lt;/B&gt;&lt;/FONT&gt;